Index RUT
P/E -
EPS (ttm) -2.01
Insider Own 39.25%
Shs Outstand 49.18M
Perf Week -15.38%
Market Cap 217.32M
Forward P/E -
EPS next Y -1.60
Insider Trans -0.03%
Shs Float 42.86M
Perf Month -26.14%
Income -107.91M
PEG -
EPS next Q -0.37
Inst Own 64.48%
Short Float 24.31%
Perf Quarter -48.41%
Sales 0.00M
P/S -
EPS this Y 32.57%
Inst Trans 7.83%
Short Ratio 16.97
Perf Half Y -59.10%
Book/sh 6.42
P/B 0.48
EPS next Y 1.06%
ROA -21.95%
Short Interest 10.42M
Perf Year 51.72%
Cash/sh 4.60
P/C 0.67
EPS next 5Y -
ROE -27.99%
52W Range 1.89 - 16.24
Perf YTD -53.33%
Dividend Est. -
P/FCF -
EPS past 5Y -209.81%
ROI -20.24%
52W High -81.03%
Beta 0.82
Dividend TTM -
Quick Ratio 15.91
Sales past 5Y -39.65%
Gross Margin -
52W Low 62.96%
ATR (14) 0.33
Dividend Ex-Date -
Current Ratio 15.91
EPS Y/Y TTM 21.46%
Oper. Margin 0.00%
RSI (14) 29.17
Volatility 9.31% 8.36%
Employees 150
Debt/Eq 0.19
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 17.17
Option/Short Yes / Yes
LT Debt/Eq 0.18
EPS Q/Q 49.96%
Payout -
Rel Volume 1.34
Prev Close 3.33
Sales Surprise -
EPS Surprise 27.94%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 614.08K
Price 3.08
SMA20 -19.17%
SMA50 -33.71%
SMA200 -57.26%
Trades
Volume 823,484
Change -7.51%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-09-24 Initiated
Rodman & Renshaw
Buy
$14
Aug-14-24 Upgrade
Raymond James
Outperform → Strong Buy
$16
Mar-22-24 Downgrade
Raymond James
Strong Buy → Outperform
$13 → $16
Dec-22-22 Downgrade
Oppenheimer
Outperform → Perform
Oct-10-22 Initiated
Canaccord Genuity
Buy
$25
Jul-28-22 Initiated
Needham
Buy
$26
Jul-18-22 Initiated
SVB Leerink
Outperform
$30
Mar-11-22 Initiated
Raymond James
Outperform
$17
Mar-08-22 Initiated
H.C. Wainwright
Buy
$25
Jan-06-22 Initiated
William Blair
Outperform
Nov-18-21 Initiated
SMBC Nikko
Outperform
$50
Jul-16-21 Initiated
Oppenheimer
Outperform
$75
Aug-04-20 Initiated
Stifel
Buy
$41
Aug-04-20 Initiated
Mizuho
Buy
$34
Aug-04-20 Initiated
Evercore ISI
Outperform
$55
Aug-04-20 Initiated
Cowen
Outperform
Show Previous Ratings
Oct-09-24 08:00AM
Sep-03-24 04:01PM
Aug-14-24 12:37PM
Aug-13-24 09:03PM
04:01PM
06:00AM
Loading…
Jul-24-24 06:00AM
Jul-16-24 06:01AM
Jul-10-24 12:00PM
Jul-01-24 10:20AM
Jun-27-24 06:00AM
Jun-13-24 04:01PM
May-10-24 02:56PM
May-09-24 10:57PM
04:01PM
May-07-24 06:30AM
04:02PM
Loading…
Apr-03-24 04:02PM
Mar-25-24 04:06PM
(Investor's Business Daily) +17.60%
-5.91%
06:30AM
Mar-23-24 05:31AM
Mar-22-24 04:03PM
(Investor's Business Daily) -31.28%
+17.60%
09:18AM
Mar-21-24 10:54PM
04:01PM
Mar-19-24 07:29AM
Feb-29-24 06:30AM
Feb-28-24 08:01AM
Feb-20-24 04:19PM
Feb-08-24 09:32AM
Feb-06-24 12:50PM
Feb-05-24 12:41PM
08:00AM
Loading…
Feb-04-24 08:00AM
Jan-09-24 10:25AM
Dec-09-23 08:31PM
Dec-08-23 12:00PM
Nov-14-23 03:56PM
Nov-09-23 04:02PM
11:38AM
Nov-07-23 08:02AM
Oct-25-23 02:06PM
Oct-18-23 10:47AM
01:18AM
Oct-17-23 08:17PM
(FierceBiotech.com) +112.16%
11:47AM
07:01AM
Oct-16-23 04:01PM
Oct-02-23 03:07PM
Aug-10-23 07:01AM
Aug-03-23 08:02AM
Jul-31-23 06:30PM
Jul-05-23 04:02PM
Jun-28-23 09:35AM
Jun-27-23 01:02PM
07:01AM
Jun-26-23 04:01PM
Jun-15-23 09:55AM
Jun-10-23 10:47AM
May-11-23 04:02PM
04:01PM
May-09-23 07:15AM
May-07-23 12:50PM
Apr-17-23 05:01PM
Apr-12-23 09:06PM
Apr-11-23 09:46AM
Mar-30-23 04:01PM
Mar-16-23 04:01PM
Feb-17-23 05:35AM
Feb-09-23 08:02AM
Jan-09-23 04:30PM
Dec-05-22 07:02AM
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
09:55AM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
10:18AM
Apr-25-22 11:19PM
(GlobeNewswire) +140.93%
-10.31%
06:04PM
05:44PM
(American City Business Journals)
04:09PM
(Investor's Business Daily)
04:01PM
03:52PM
10:49AM
08:34AM
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hager Alicia J. Chief Legal Officer Jul 16 '24 Sale 8.00 3,396 27,168 103,819 Jul 18 04:22 PM Trager James Chief Scientific Officer Jun 18 '24 Sale 5.60 456 2,554 150,959 Jun 20 05:04 PM HASTINGS PAUL J Chief Executive Officer Jun 18 '24 Sale 5.60 1,770 9,912 240,737 Jun 20 05:03 PM Shook David Chief Medical Officer Jun 18 '24 Sale 5.60 456 2,554 116,524 Jun 20 05:03 PM Hager Alicia J. Chief Legal Officer Jun 18 '24 Sale 5.60 727 4,071 107,215 Jun 20 05:02 PM Brandenberger Ralph Chief Technical Officer Jun 18 '24 Sale 5.60 229 1,282 79,743 Jun 20 05:01 PM RA CAPITAL MANAGEMENT, L.P. Director Mar 27 '24 Buy 10.00 3,000,000 30,000,000 10,050,818 Mar 29 05:38 PM George Simeon Director Mar 27 '24 Buy 10.00 2,000,000 20,000,000 1,548,341 Mar 28 04:30 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Option Exercise 3.89 6,763 26,308 88,339 Mar 05 04:26 PM Brandenberger Ralph Chief Technical Officer Mar 01 '24 Sale 12.51 8,367 104,671 79,972 Mar 05 04:26 PM Trager James Chief Scientific Officer Feb 12 '24 Sale 12.00 4,143 49,716 149,415 Feb 14 09:12 PM Shook David Chief Medical Officer Jan 16 '24 Sale 8.74 3,552 31,044 114,980 Jan 18 04:45 PM Trager James Chief Scientific Officer Jan 16 '24 Sale 8.74 4,560 39,854 153,558 Jan 18 04:43 PM Brandenberger Ralph Chief Technical Officer Jan 16 '24 Sale 8.74 2,512 21,955 81,576 Jan 18 04:40 PM HASTINGS PAUL J Chief Executive Officer Jan 16 '24 Sale 8.74 9,697 84,752 390,507 Jan 18 04:40 PM Hager Alicia J. Chief Legal Officer Jan 16 '24 Sale 8.74 4,554 39,802 107,942 Jan 18 04:38 PM
Index RUT
P/E 12.90
EPS (ttm) 1.29
Insider Own 3.33%
Shs Outstand 46.48M
Perf Week -2.47%
Market Cap 765.71M
Forward P/E 5.63
EPS next Y 2.95
Insider Trans -0.33%
Shs Float 44.59M
Perf Month 6.89%
Income 63.59M
PEG 1.19
EPS next Q 0.70
Inst Own 107.79%
Short Float 13.77%
Perf Quarter -21.92%
Sales 690.31M
P/S 1.11
EPS this Y 6.32%
Inst Trans 6.12%
Short Ratio 5.51
Perf Half Y -39.24%
Book/sh 19.07
P/B 0.87
EPS next Y -1.37%
ROA 3.99%
Short Interest 6.14M
Perf Year -41.26%
Cash/sh 8.76
P/C 1.89
EPS next 5Y 10.80%
ROE 7.54%
52W Range 11.16 - 35.95
Perf YTD -50.80%
Dividend Est. -
P/FCF 4.14
EPS past 5Y -
ROI 4.19%
52W High -53.82%
Beta 0.83
Dividend TTM -
Quick Ratio 5.70
Sales past 5Y 15.46%
Gross Margin 65.75%
52W Low 48.69%
ATR (14) 0.67
Dividend Ex-Date -
Current Ratio 6.82
EPS Y/Y TTM 1451.33%
Oper. Margin 14.65%
RSI (14) 52.73
Volatility 3.71% 3.96%
Employees 712
Debt/Eq 0.74
Sales Y/Y TTM 3.15%
Profit Margin 9.21%
Recom 2.78
Target Price 18.50
Option/Short Yes / Yes
LT Debt/Eq 0.73
EPS Q/Q -21.44%
Payout 0.00%
Rel Volume 0.51
Prev Close 16.87
Sales Surprise 2.47%
EPS Surprise 27.34%
Sales Q/Q 5.05%
Earnings Nov 06 AMC
Avg Volume 1.11M
Price 16.60
SMA20 -0.46%
SMA50 8.44%
SMA200 -30.52%
Trades
Volume 573,104
Change -1.60%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Downgrade
Truist
Buy → Sell
$30 → $8
Aug-12-24 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$37 → $14
Aug-12-24 Downgrade
Raymond James
Outperform → Mkt Perform
Aug-12-24 Downgrade
Piper Sandler
Overweight → Neutral
$42 → $11
Aug-12-24 Downgrade
JP Morgan
Overweight → Underweight
$45 → $10
Jul-03-24 Downgrade
Barclays
Overweight → Equal Weight
$38 → $25
Mar-07-24 Resumed
JP Morgan
Overweight
$80 → $45
Dec-20-23 Initiated
Raymond James
Outperform
$42
Aug-03-23 Upgrade
TD Cowen
Market Perform → Outperform
$50
Jan-31-23 Resumed
Wedbush
Outperform
$88 → $60
Oct-21-22 Resumed
Jefferies
Buy
$66
Jan-03-22 Resumed
JP Morgan
Overweight
$75 → $83
Jul-26-21 Upgrade
JP Morgan
Neutral → Overweight
$75
Apr-21-21 Resumed
JP Morgan
Neutral
$70
Apr-09-21 Initiated
Berenberg
Buy
$93
Apr-07-21 Resumed
RBC Capital Mkts
Outperform
$86
Feb-11-21 Downgrade
Northland Capital
Outperform → Market Perform
$72 → $75
Jan-21-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$75
Sep-21-20 Upgrade
Northland Capital
Market Perform → Outperform
$58 → $67
Jul-06-20 Reiterated
Needham
Buy
$52 → $64
Show Previous Ratings
Oct-30-24 08:00AM
Oct-21-24 08:38AM
08:00AM
Oct-07-24 08:00AM
Oct-03-24 08:00AM
08:00AM
Loading…
Sep-26-24 08:00AM
Sep-25-24 08:15AM
Sep-09-24 04:00PM
Aug-09-24 03:21PM
Jul-31-24 10:49AM
Jul-30-24 08:58PM
04:14PM
(Associated Press Finance)
04:00PM
Jul-29-24 06:00AM
Jul-23-24 08:00AM
03:52AM
Loading…
03:52AM
Jul-17-24 09:50AM
Jul-12-24 10:41AM
Jul-10-24 04:19PM
Jun-14-24 02:41AM
Jun-06-24 11:31AM
May-30-24 08:00AM
May-10-24 07:00AM
May-08-24 04:05PM
11:35AM
09:33AM
03:47AM
May-07-24 09:01PM
06:03PM
05:30PM
04:13PM
Loading…
04:13PM
(Associated Press Finance)
04:00PM
08:00AM
Apr-30-24 08:00AM
Apr-04-24 11:33AM
Apr-02-24 08:00AM
Mar-14-24 08:23AM
Mar-13-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:00AM
Mar-04-24 08:28PM
Mar-01-24 08:38AM
06:05AM
12:28AM
(Thomson Reuters StreetEvents)
Feb-29-24 10:00AM
09:15AM
08:32AM
08:26AM
(Associated Press Finance)
08:00AM
Feb-22-24 08:00AM
Feb-15-24 08:36AM
Feb-07-24 08:00AM
Feb-01-24 10:45AM
Jan-05-24 12:21PM
Jan-04-24 05:00PM
Jan-03-24 08:00AM
Dec-21-23 07:30AM
Dec-06-23 11:13AM
Nov-13-23 10:10AM
Nov-10-23 07:30AM
Nov-07-23 08:00AM
Nov-04-23 10:28AM
Nov-02-23 12:34PM
10:00AM
08:23AM
(Associated Press Finance)
08:00AM
Oct-26-23 08:00AM
Oct-12-23 08:00AM
Oct-10-23 08:00AM
Oct-02-23 08:00AM
Sep-27-23 12:07PM
11:50AM
Sep-26-23 04:30PM
Sep-06-23 08:00AM
Aug-03-23 10:03AM
Aug-02-23 12:45PM
08:11AM
08:00AM
Jul-28-23 02:56PM
Jul-26-23 08:00AM
Jun-21-23 08:00PM
Jun-02-23 11:31AM
May-31-23 08:00AM
May-09-23 08:00AM
May-03-23 11:42PM
(Thomson Reuters StreetEvents) -7.17%
05:25PM
03:11PM
08:11AM
08:00AM
Apr-26-23 08:00PM
08:00AM
Apr-20-23 09:20AM
08:00AM
Apr-19-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:00AM
Mar-30-23 11:30AM
Mar-29-23 08:00AM
Mar-27-23 08:00AM
Mar-24-23 08:50AM
Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GAUGLER DARYL Chief Operating Officer Sep 13 '24 Sale 12.86 500 6,430 115,700 Sep 13 08:29 PM GAUGLER DARYL Officer Sep 13 '24 Proposed Sale 12.86 500 6,430 Sep 13 10:17 AM BIGAL MARCELO Director Aug 16 '24 Buy 13.25 1,512 20,034 10,142 Aug 19 08:25 AM Brege Laura Director Aug 16 '24 Buy 12.81 1,000 12,810 17,552 Aug 19 08:25 AM YANG MICHAEL J. Director Aug 14 '24 Buy 12.90 2,000 25,800 7,230 Aug 14 04:35 PM Lee Frank D. Chief Executive Officer Aug 12 '24 Buy 12.10 8,264 99,994 107,784 Aug 13 04:55 PM Froimson Mark Director Aug 12 '24 Buy 11.58 1,400 16,212 14,473 Aug 12 08:33 PM BIGAL MARCELO Director Aug 12 '24 Buy 12.01 3,400 40,834 8,630 Aug 12 08:33 PM SLONIN JONATHAN Chief Medical Officer Aug 02 '24 Sale 20.05 945 18,947 94,307 Aug 02 06:00 PM SLONIN JONATHAN Officer Aug 02 '24 Proposed Sale 20.05 945 18,947 Aug 02 10:09 AM SLONIN JONATHAN Chief Medical Officer Jul 02 '24 Sale 28.25 2,836 80,117 95,557 Jul 03 06:52 PM RIKER LAUREN Senior Vice President, Finance Jun 12 '24 Sale 28.72 3,970 114,018 38,075 Jun 13 06:15 PM SLONIN JONATHAN Chief Medical Officer Jun 11 '24 Sale 28.57 5,012 143,193 44,569 Jun 13 06:15 PM GAUGLER DARYL Chief Operating Officer Jun 13 '24 Sale 28.38 1,000 28,380 116,040 Jun 13 06:13 PM HASTINGS PAUL J Director Jun 13 '24 Sale 28.38 880 24,974 12,724 Jun 13 06:13 PM WILLIAMS KRISTEN Chief Administrative Officer Jun 13 '24 Sale 28.38 7,452 211,488 102,912 Jun 13 06:12 PM PACE GARY W Director Mar 08 '24 Sale 30.60 90,000 2,754,000 22,127 Mar 08 05:33 PM PACE GARY W Director Mar 07 '24 Sale 30.81 28,257 870,598 112,127 Mar 08 05:33 PM PACE GARY W Director Mar 06 '24 Sale 29.67 1,066 31,628 140,384 Mar 08 05:33 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite